UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 2, 2018

Tetraphase Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)

Delaware	**001-35837**	**20-5276217**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

480 Arsenal Way **Watertown, Massachusetts**	**02472**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (617) 715-3600

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 2, 2018, Tetraphase Pharmaceuticals, Inc. (the "Company") announced that it had completed its submission of a New Drug Application (the "NDA") for intravenous ("IV") eravacycline for the treatment of complicated intra-abdominal infections ("cIAI"). The NDA submission was supported by data from the Company's phase 3 clinical trial known as IGNITE4 evaluating the efficacy and safety of twice-daily IV eravacycline compared to meropenem for the treatment of patients with cIAI and by data from the Company's phase 3 clinical trial known as IGNITE1 evaluating the efficacy and safety of twice-daily IV eravacycline compared to ertapenem for the treatment of patients with cIAI.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Maria D. Stahl
Maria D. Stahl
Senior Vice President, General Counsel

Date: January 5, 2018